|
1
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Decio A and Giavazzi R: Orthotopic model
of ovarian cancer. Methods Mol Biol. 1464:139–149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Despierre E, Lambrechts D, Neven P, Amant
F, Lambrechts S and Vergote I: The molecular genetic basis of
ovarian cancer and its roadmap towards a better treatment. Gynecol
Oncol. 117:358–365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lässer C: Exosomal RNA as biomarkers and
the therapeutic potential of exosome vectors. Expert Opin Biol
Ther. 12 (Suppl 1):S189–S197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Petrovčíková E, Vičíková K and Leksa V:
Extracellular vesicles-biogenesis, composition, function, uptake
and therapeutic applications. Biologia. 73:437–448. 2018.
View Article : Google Scholar
|
|
11
|
Valadi H, Ekström K, Bossios A, Sjöstrand
M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between cells.
Nat Cell Biol. 9:654–659. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pisitkun T, Shen RF and Knepper MA:
Identification and proteomic profiling of exosomes in human urine.
Proc Natl Acad USA. 101:13368–13373. 2004. View Article : Google Scholar
|
|
13
|
Suetsugu A, Honma K, Saji S, Moriwaki H,
Ochiya T and Hoffman RM: Imaging exosome transfer from breast
cancer cells to stroma at metastatic sites in orthotopic nude-mouse
models. Adv Drug Deliv Rev. 65:383–390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Subra C, Grand D, Laulagnier K, Stella A,
Lambeau G, Paillasse M, De Medina P, Monsarrat B, Perret B,
Silvente-Poirot S, et al: Exosomes account for vesicle-mediated
transcellular transport of activatable phospholipases and
prostaglandins. J Lipid Res. 51:2105–2120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsuo K, Machida H, Mandelbaum RS,
Konishi I and Mikami M: Validation of the 2018 FIGO cervical cancer
staging system. Gynecol Oncol. 152:87–93. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang L, Feng Z, Wang X, Wang X and Zhang
X: DEGseq: An R package for identifying differentially expressed
genes from RNA-seq data. Bioinformatics. 26:136–138. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife 4. 2015. View Article : Google Scholar
|
|
18
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
3:e2642004. View Article : Google Scholar
|
|
19
|
Krüger J and Rehmsmeier M: RNAhybrid:
microRNA target prediction easy, fast and flexible. Nucleic Acids
Res. 34:451–454. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Young MD, Wakefield MJ, Smyth GK and
Oshlack A: Gene ontology analysis for RNA-seq: Accounting for
selection bias. Genome Biol. 11:R142010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanehisa M, Araki M, Goto S, Hattori M,
Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T
and Yamanishi Y: KEGG for linking genomes to life and the
environment. Nucleic Acids Research 36 (Database Issue). D480–D484.
2008.
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pant S, Hilton H and Burczynski ME: The
multifaceted exosome: Biogenesis, role in normal and aberrant
cellular function, and frontiers for pharmacological and biomarker
opportunities. Biochem Pharmacol. 83:1484–1494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koshiyama M, Matsumura N and Konishi I:
Subtypes of ovarian cancer and ovarian cancer screening.
Diagnostics (Basel). 7:E122017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mandai M, Yamaguchi K, Matsumura N, Baba T
and Konishi I: Ovarian cancer in endometriosis: Molecular biology,
pathology, and clinical management. Int J Clin Oncol. 14:383–391.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weiland M, Gao XH, Zhou L and Mi QS: Small
RNAs have a large impact: Circulating microRNAs as biomarkers for
human diseases. RNA Biol. 9:850–859. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He Y, Lin J, Kong D, Huang M, Xu C, Kim
TK, Etheridge A, Luo Y, Ding Y and Wang K: Current state of
circulating MicroRNAs as cancer biomarkers. Clin Chem.
61:1138–1155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakamura K, Sawada K, Yoshimura A, Kinose
Y, Nakatsuka E and Kimura T: Clinical relevance of circulating
cell-free microRNAs in ovarian cancer. Mol Cancer. 15:482016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang H, Wang T, Shi W, Yuan L, Chen L and
Li Z: Comprehensive analysis on diagnostic value of circulating
miRNAs for patients with ovarian cancer. Oncotarget. 8:66620–66628.
2017.PubMed/NCBI
|
|
30
|
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK,
Pritchard CC, Gibson DF, Mitchell PS, Bennett CF,
Pogosova-Agadjanyan EL, Stirewalt DL, et al: Argonaute2 complexes
carry a population of circulating microRNAs independent of vesicles
in human plasma. Proc Natl Acad Sci USA. 108:5003–5008. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vaksman O, Tropé C, Davidson B and Reich
R: Exosome-derived miRNAs and ovarian carcinoma progression.
Carcinogenesis. 35:2113–2120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
EL Andaloussi S, Mäger I, Breakefield XO
and Wood MJ: Extracellular vesicles: Biology and emerging
therapeutic opportunities. Nat Rev Drug Discov. 12:347–357. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van der Pol E, Boing AN, Harrison P, Sturk
A and Nieuwland R: Classification, functions, and clinical
relevance of extracellular vesicles. Pharmacol Rev. 64:676–705.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Keller S, Sanderson MP, Stoeck A and
Altevogt P: Exosomes: From biogenesis and secretion to biological
function. Immunol Lett. 107:102–108. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Szajnik M, Derbis M, Lach M, Patalas P,
Michalak M, Drzewiecka H, Szpurek D, Nowakowski A, Spaczynski M,
Baranowski W and Whiteside TL: Exosomes in plasma of patients with
ovarian carcinoma: Potential biomarkers of tumor progression and
response to therapy. Gynecol Obstet (Sunnyvale). (Suppl
4):S32013.
|
|
36
|
Hessvik NP and Llorente A: Current
knowledge on exosome biogenesis and release. Cell Mol Life Sci.
75:193–208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Taylor DD and Gercel-Taylor C: MicroRNA
signatures of tumor-derived exosomes as diagnostic biomarkers of
ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yoshimura A, Sawada K, Nakamura K, Kinose
Y, Nakatsuka E, Kobayashi M, Miyamoto M, Ishida K, Matsumoto Y,
Kodama M, et al: Exosomal miR-99a-5p is elevated in sera of ovarian
cancer patients and promotes cancer cell invasion by increasing
fibronectin and vitronectin expression in neighboring peritoneal
mesothelial cells. BMC Cancer. 18:10652018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hang W, Feng Y, Sang Z, Yang Y, Zhu Y,
Huang Q and Xi X: Downregulation of miR-145-5p in cancer cells and
their derived exosomes may contribute to the development of ovarian
cancer by targeting CT. Int J Mol Med. 43:256–266. 2019.PubMed/NCBI
|
|
40
|
Pan C, Stevic I, Müller V, Ni Q,
Oliveira-Ferrer L, Pantel K and Schwarzenbach H: Exosomal microRNAs
as tumor markers in epithelial ovarian cancer. Mol Oncol.
12:1935–1948. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang W, Yang J, Xiang YY, Pi J and Bian J:
Overexpression of Hsa-miR-320 is associated with invasion and
metastasis of ovarian cancer. J Cell Biochem. 118:3654–3661. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zheng H, Liu JY, Song FJ and Chen KX:
Advances in circulating microRNAs as diagnostic and prognostic
markers for ovarian cancer. Cancer Biol Med10. 123–130. 2013.
|
|
43
|
Duan Y, Dong Y, Dang R, Hu Z, Yang Y, Hu Y
and Cheng J: MiR-122 inhibits epithelial mesenchymal transition by
regulating P4HA1 in ovarian cancer cells. Cell Biol Int.
42:1564–1574. 2018. View Article : Google Scholar : PubMed/NCBI
|
